Article Content
MarketFlick Insights
Whey price surge and weight loss drugs threaten Applied Nutrition s margins
At a glance
- Applied Nutrition delivered robust revenue and profit growth and raised nearterm earnings guidance to around £49m.
- Whey protein prices have risen roughly fivefold recently, creating a material inputcost headwind for protein supplement makers.
- The popularity of GLP1 weightloss drugs (e.g., Wegovy, Mounjaro) has increased consumer demand for protein to preserve muscle mass, fueling higher whey demand.
- Supply constraints in the whey market mean elevated prices could persist and compress margins unless input costs moderate or companies adjust pricing/strategy.
- Broader consumer sectors, including food and beverage and alcohol, are seeing demand shifts linked to the mass adoption of GLP1 drugs.
Market impact
Applied Nutrition, the UK proteinshake maker that listed on the London Stock Exchange in 2024, has warned that a recent fivefold rise in whey protein prices will dent margins next year even as it upgrades nearterm earnings forecasts.
In unaudited fullyear results for the 12 months to August, the Merseysidebased group said adjusted pretax profit rose by more than 40 per cent a performance the company described as considerably ahead of consensus market expectations. Revenue is set to top £200m for the first time in its history and the firm expects adjusted earnings to increase by a further 13 per cent to around £49m. Shares jumped about 7.5 per cent at the open on the trading update.
Despite that positive momentum, Applied Nutrition flagged significantly higher input costs driven by a dramatic increase in whey protein prices. The cost spike reflects a surge in global demand combined with constrained supply, with prices rising roughly fivefold in recent years. Whey is the predominant protein ingredient in the bars, shakes and supplements that underpin Applied Nutritions product range, so sustained higher prices are expected to weigh on margins in the year ahead.
Why demand has jumped
A key driver of stronger whey demand has been the rapid rollout of GLP1 weightloss drugs, notably branded treatments such as Wegovy and Mounjaro. One documented side effect of GLP1 therapies is loss of muscle mass for some patients, which has prompted many users to adopt higherprotein diets and increase resistance training to preserve muscle while losing weight.
That behavioural change more consumers seeking proteinrich foods and supplements has collided with a largely fixed global whey supply chain, pushing raw material prices higher and creating a new cost pressure for companies whose products depend on dairyderived protein.
The whey price dynamic is one example of how weightloss medicines are reshaping demand across a range of consumer categories. Food and beverage giants have responded by developing nutrientdense ready meals aimed at people with reduced appetites who still need balanced nutrition. Investment managers have also signalled secondorder effects: some have reduced exposure to alcohol stocks, anticipating lower consumption among users of these drugs.
Applied Nutritions results underline the tension many consumer brands now face robust topline growth and strong consumer interest in protein products, but rising commodity costs that could compress profits unless supply and pricing conditions stabilise. The companys upgraded profit guidance shows resilience, but the firm and investors will be watching whey markets and the broader impact of GLP1 treatments closely as they assess margins and strategy for the year ahead.
